|
Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies. |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Honoraria - Foundation medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda |
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - The Chinese University of Hong Kong |
Leadership - AstraZeneca; Hutchison MediPharma; Sanomics Limited |
Stock and Other Ownership Interests - Hutchison MediPharma; Sanomics Limited |
Honoraria - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Fishawack Facilitate; Hutchison MediPharma; Ignyta; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Vertex |
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Hutchison MediPharma; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Xcovery (Inst) |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |